[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559719":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":53,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":80,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Aventusoft, LLC.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HEMOTAG with Standard of Care in DM patients",null,"HEMOTAG with Standard of Care: To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.",[13],"Device: Hemotag",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Hemotag","Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"CINDY KOBER, BS","CONTACT","954-399-3335","cindy@aventusoft.com",{"name":27,"role":23,"phone":24,"phoneExt":10,"email":28},"Ali Hamadeh, MS","ali@aventusoft.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Metabolic Research Institute, Inc","RECRUITING","West Palm Beach","Florida","33401'","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-80.05337,26.71534,{"lat":42,"lon":41},[45,50],{"name":46,"role":23,"phone":47,"phoneExt":48,"email":49},"Alayzah Garcia, BA","561-802-3060","8032","agarcia@metabolic-institute.com",{"name":51,"role":52,"phone":10,"phoneExt":10,"email":10},"Barry Horowitz, MD","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[56],{"name":57,"class":58},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100559719","primary-individualized-evaluation-of-cardiovascular-events-in-patients-with-diabetes-mellitus-using-hemotag-100559719",false,"NCT06567795","PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG","Prospective, Multi-center, Longitudinal, Study for PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG","PRIZETAG","Inclusion Criteria:\n\n1. Adult patients older than 40 years of age.\n2. Diagnosis of Type 2 Diabetes Mellitus (insulin dependent or non-insulin dependent) for at least 5 years.\n3. Diagnosis of Cardiovascular Disease (Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease, etc…) --OR--\n\n   Have one (1) of the following concomitant medical diagnoses:\n   1. Diabetic Retinopathy (proliferative or non-proliferative)\n   2. Diabetic Nephropathy (eGFR \\<60 mL\u002Fmin\u002F1.73m2 and\u002For urine albumin\u002Fcreatinine ratio ≥30 mg\u002Fg)\n   3. Diabetic Neuropathy\n   4. Elevated High-sensitivity C-reactive protein (hs-CRP) --AND--\n\n      Have a history of two (2) or more of the following:\n   5. Diagnosis of Hypertension for at least 6 months or more (treated or untreated)\n   6. Hypercholesterolemia (LDL-C \\>100 mg\u002FdL)\n   7. Obesity (Body Mass Index (BMI) ≥ 27 for men or ≥ 22 for women)\n   8. History of Smoking\n4. Willingness to undergo HEMOTAG evaluation.\n5. Willingness to undergo Standard of Care visits\u002Fassessments and NT-pro BNP lab evaluations.\n6. Willingness to conduct at-home HEMOTAG evaluations at least three days per week within a 30-day time period after the completion of the Baseline Visit, after the 6 month visit and following discharge from any hospitalizations due to a cardiac events during the 12 month study period.\n7. Willingness to receive and return shipping of the HEMOTAG KIT at each time point as required by the protocol\n8. Able to give informed consent.\n\nExclusion Criteria:\n\n1. Terminal condition with life expectancy less than 12 months as determined by investigator.\n2. Physical deformity in the chest area or lesion that may prevent proper HEMOTAG application or adjustment.\n3. Illness\u002F Condition which may be aggravated or cause significant discomfort to the patient by the application of the HEMOTAG (skin issues, e.g. Intolerance to use of skin electrodes).\n4. Participant enrolled in another interventional study (observational or registries are not excluded).\n5. Prisoners and wards of the state.\n6. Impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator\\'s assessment.\n7. Participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (Exclude participants who necessitate the involvement of a legally authorized representative.)\n8. Inability to provide informed consent (Must speak English).\n9. Women who are pregnant or are planning to become pregnant during the study.\n10. Women of childbearing potential who are unwilling or unable to comply with contraception measures.","ALL","40 Years",{"count":70,"type":71},189,"ESTIMATED","OBSERVATIONAL","To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.",[75,76,77,78,79],"Diabetes Mellitus Type 2","Cardiovascular Diseases","Coronary Artery Disease","Cerebrovascular Disease","Peripheral Artery Disease",[81,76,77],"Diabetes Mellitus","2024-08-21",{"date":84,"type":85},"2024-08-23","ACTUAL",{"date":87,"type":85},"2024-03-14",{"date":89,"type":71},"2027-03-18",{"name":5,"class":6},1]